Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Metformin577 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A27610 | 17910660 | Pediatr Transplant | Recurrence of non-alcoholic steatohepatitis after liver transplantation in a 13-yr-old boy. | 2007 | Details |
| A27676 | 17691915 | Curr Drug Discov Technol | Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). | 2007 | Details |
| A27792 | 17420951 | Dig Dis Sci | The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. | 2007 | Details |
| A27850 | 17253544 | Cochrane Database Syst Rev | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. | 2007 | Details |
| A27868 | 17203528 | World J Gastroenterol | Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. | 2006 | Details |
| A27912 | 17033514 | J Pediatr Gastroenterol Nutr | Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. | 2006 | Details |
| A27931 | 16968800 | J Clin Endocrinol Metab | Review: The role of insulin resistance in nonalcoholic fatty liver disease. | 2006 | Details |
| A27932 | 16959622 | J Formos Med Assoc | Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. | 2006 | Details |
| A27935 | 16953843 | Liver Int | Incretin mimetics as a novel therapeutic option for hepatic steatosis. | 2006 | Details |
| A27938 | 16942668 | Curr Treat Options Gastroenterol | Nonalcoholic Fatty Liver Disease (NAFLD): Approach in the Adolescent Patient. | 2006 | Details |
| A27964 | 16865780 | World J Gastroenterol | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. | 2006 | Details |
| A27984 | 16796890 | Zhonghua Yi Xue Za Zhi | [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. | 2006 | Details |
| A28016 | 16709309 | Curr Med Res Opin | Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. | 2006 | Details |
| A28044 | 16610015 | World J Gastroenterol | Treatment of nonalcoholic fatty liver disease. | 2006 | Details |
| A28059 | 16540770 | J Clin Gastroenterol | Therapy of NAFLD: insulin sensitizing agents. | 2006 | Details |
| A28077 | 16503761 | Expert Opin Investig Drugs | Recent findings concerning thiazolidinediones in the treatment of diabetes. | 2006 | Details |
| A28079 | 16672828 | J Clin Gastroenterol | Therapy of NAFLD: Insulin Sensitizing Agents. | 2006 | Details |
| A28112 | 16393299 | Aliment Pharmacol Ther | Review article: Drug therapy for non-alcoholic fatty liver disease. | 2006 | Details |
| A28145 | 16265156 | Nat Clin Pract Gastroenterol Hepatol | Treatment strategies in nonalcoholic fatty liver disease. | 2005 | Details |
| A28156 | 16250043 | Hepatology | Insulin resistance: a metabolic pathway to chronic liver disease. | 2005 | Details |
| A28159 | 16247633 | Internist (Berl) | [Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis]. | 2005 | Details |
| A28165 | 16231594 | Eur Rev Med Pharmacol Sci | The treatment of NAFLD. | 2006 | Details |
| A28179 | 16225470 | Aliment Pharmacol Ther | Review article: the treatment of fatty liver disease associated with the metabolic syndrome. | 2005 | Details |
| A28180 | 16225469 | Aliment Pharmacol Ther | Review article: the metabolic syndrome and non-alcoholic fatty liver disease. | 2005 | Details |
| A28219 | 16095853 | J Ethnopharmacol | Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. | 2005 | Details |
| A28273 | 15842582 | Am J Gastroenterol | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. | 2005 | Details |
| A28284 | 15801922 | Aliment Pharmacol Ther | A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. | 2005 | Details |
| A28319 | 15696851 | Scand J Gastroenterol Suppl | Non-alcoholic fatty liver disease: a brief review. | 2004 | Details |
| A28339 | 15598336 | Pediatr Transplant | Non-alcoholic steatohepatitis in children. | 2004 | Details |
| A28346 | 15561641 | Best Pract Res Clin Gastroenterol | Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. | 2004 | Details |
| A28381 | 15331063 | Clin Liver Dis | Nonalcoholic fatty liver disease in the pediatric population. | 2004 | Details |
| A28392 | 15248381 | Dig Liver Dis | Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. | 2004 | Details |
| A28399 | 15225167 | Aliment Pharmacol Ther | Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. | 2004 | Details |
| A28416 | 15114291 | Ann Hepatol | Treatment of nonalcoholic fatty liver disease. | 2004 | Details |
| A28426 | 15046183 | Dig Liver Dis | Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? | 2004 | Details |
| A28479 | 12739988 | Expert Opin Pharmacother | Current best treatment for non-alcoholic fatty liver disease. | 2003 | Details |
| A28507 | 12406446 | Best Pract Res Clin Gastroenterol | Treatment of non-alcoholic steatohepatitis. | 2002 | Details |
| A28534 | 22822324 | Ochsner J | Nonalcoholic Fatty liver disease from the perspective of an internist. | 2002 | Details |
| A28550 | 11567710 | Lancet | Metformin in non-alcoholic steatohepatitis. | 2001 | Details |
| A29479 | 34016612 | Diabetes Care | Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. | 2021 | Details |
| A31090 | 31248114 | Int J Mol Sci | Biphasic Effect of Sildenafil on Energy Sensing is Mediated by Phosphodiesterases 2 and 3 in Adipocytes and Hepatocytes. | 2019 | Details |
| A31189 | 31068812 | Front Pharmacol | Matrine Protects Against MCD-Induced Development of NASH via Upregulating HSP72 and Downregulating mTOR in a Manner Distinctive From Metformin. | 2019 | Details |
| A32060 | 29278707 | Biochem Biophys Res Commun | Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. | 2017 | Details |
| A34925 | 24829630 | Middle East J Dig Dis | Metformin in nonalcoholic steatohepatitis: a randomized controlled trial. | 2012 | Details |
| A35922 | 21180541 | Therap Adv Gastroenterol | The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. | 2009 | Details |
| A36439 | 18197877 | Hepatol Res | Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. | 2008 | Details |
| A36751 | 17335677 | Curr Gastroenterol Rep | Treatment of fibrosis in nonalcoholic fatty liver disease. | 2007 | Details |
| A36989 | 16768125 | Nihon Rinsho | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. | 2006 | Details |
| A37472 | 15605307 | Semin Liver Dis | Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. | 2004 | Details |
| A37691 | 15106708 | Indian J Gastroenterol | Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report. | 2004 | Details |
| A37708 | 15066643 | Eur J Intern Med | Non-alcoholic steatohepatitis: review of a growing medical problem. | 2004 | Details |
| A38186 | 11944630 | Semin Gastrointest Dis | Diabetes mellitus, obesity, and hepatic steatosis. | 2002 | Details |
| A42614 | 34015974 | Expert Rev Clin Pharmacol | Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. | 2021 | Details |
| A42625 | 33981216 | Front Pharmacol | Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents. | 2021 | Details |
| A43281 | 32072735 | Diabetes Obes Metab | Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. | 2020 | Details |
| A43392 | 31850557 | Aliment Pharmacol Ther | Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyond. | 2020 | Details |
| A43475 | 31613385 | Hepatology | Reply. | 2020 | Details |
| A43478 | 31610029 | Hepatology | Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43518 | 31532551 | Aliment Pharmacol Ther | Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply. | 2019 | Details |
| A43519 | 31532548 | Aliment Pharmacol Ther | Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. | 2019 | Details |
| A43558 | 31414538 | Aliment Pharmacol Ther | Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis. | 2019 | Details |
| A43578 | 31359473 | Aliment Pharmacol Ther | Letter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism? | 2019 | Details |
| A43731 | 31006135 | Hepatology | Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. | 2019 | Details |
| A43833 | 30763050 | Am Fam Physician | Metformin for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | 2019 | Details |
| A43874 | 30625338 | Toxicol Appl Pharmacol | Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation. | 2019 | Details |
| A44025 | 30119271 | Biomed Pharmacother | Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. | 2018 | Details |
| A44063 | 29998503 | Aliment Pharmacol Ther | Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD). | 2018 | Details |
| A44186 | 29474539 | Endocrinology | miR-1224-5p Enhances Hepatic Lipogenesis by Targeting Adenosine Monophosphate-Activated Protein Kinase α1 in Male Mice. | 2018 | Details |
| A44345 | 28901968 | Curr Opin Obstet Gynecol | Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. | 2017 | Details |
| A44437 | 28631945 | Curr Med Res Opin | Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr Med Res Opin 2017;33:797-801. | 2017 | Details |
| A44501 | 28459036 | Indian J Endocrinol Metab | Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. | 2020 | Details |
| A44806 | 27256522 | Clin Endocrinol (Oxf) | Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. | 2016 | Details |
| A44872 | 27013659 | J Biol Chem | Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1. | 2016 | Details |
| A44900 | 26914713 | Cancer | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. | 2016 | Details |
| A45045 | 26308759 | Altern Ther Health Med | Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health. | 2015 | Details |
| A45300 | 25293340 | Curr Treat Options Cardiovasc Med | Childhood obesity and insulin resistance: how should it be managed? | 2014 | Details |
| A45411 | 24748831 | J Ginseng Res | AMP-activated protein kinase: An emerging target for ginseng. | 2013 | Details |
| A45453 | 24485856 | Diabetes Res Clin Pract | Liver disease and diabetes: association, pathophysiology, and management. | 2014 | Details |
| A45524 | 24143116 | Diabetes Metab Syndr Obes | Hepatic function and the cardiometabolic syndrome. | 2013 | Details |
| A45697 | 23222203 | Pol Arch Med Wewn | Metformin superior to low‑fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis. | 2012 | Details |
| A45779 | 22801247 | J Investig Med | Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. | 2012 | Details |
| A45830 | 22488764 | Hepatology | The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. | 2012 | Details |
| A45907 | 22149573 | Expert Rev Gastroenterol Hepatol | Medical therapy for nonalcoholic fatty liver disease in children and adolescents. | 2012 | Details |
| A45915 | 22101559 | Curr Opin Lipidol | Current world literature. | 2011 | Details |
| A45938 | 21953015 | Hepatology | Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials? | 2011 | Details |
| A45944 | 21917277 | Metabolism | Adiponectin levels in nonalcoholic fatty liver disease. | 2011 | Details |
| A45961 | 21832111 | J Clin Endocrinol Metab | Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. | 2011 | Details |
| A45980 | 21750513 | Nat Rev Gastroenterol Hepatol | Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way? | 2011 | Details |
| A46059 | 21366813 | Pediatr Diabetes | Use of metformin in pediatric age. | 2011 | Details |
| A46100 | 21105109 | Hepatology | Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. | 2010 | Details |
| A46142 | 20798858 | J Obes | Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents. | 2010 | Details |
| A46181 | 20520981 | Arq Gastroenterol | The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. | 2010 | Details |
| A46183 | 20490678 | Dig Dis Sci | Metformin: a therapeutic option for treating nonalcoholic fatty liver disease. | 2010 | Details |
| A46192 | 20452916 | J Am Pharm Assoc (2003) | Clarifying metformin's role and risks in liver dysfunction. | 2010 | Details |
| A46321 | 19553925 | Obesity (Silver Spring) | Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. | 2009 | Details |
| A46381 | 19161394 | Pediatr Diabetes | Treatment of non-alcoholic fatty liver disease in children: swim at your own risk. | 2009 | Details |
| A46410 | 21180527 | Therap Adv Gastroenterol | Treatment options for nonalcoholic Fatty liver disease. | 2008 | Details |
| A46444 | 18619079 | Am Fam Physician | Gastrointestinal complications of diabetes. | 2008 | Details |
| A46560 | 17592439 | Minerva Med | Comprehensive clinical management of polycystic ovary syndrome. | 2007 | Details |
| A46587 | 17429734 | Dig Dis Sci | The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. | 2007 | Details |